Zuellig Pharma: A Sustainable Approach to Healthcare Access Through Innovative Solutions
BioSpectrum Asia|October 2024
The equitable distribution of medicines and their accessibility are critical to the resilience of the healthcare system.
Zuellig Pharma: A Sustainable Approach to Healthcare Access Through Innovative Solutions

However, disparities in access and equity continue to exist and these are pertinent to address, especially as healthcare disruptions can negatively impact an economy's public health and patient care.

As powerful catalysts of transformational change, the COVID-19 pandemic tested the resilience and flexibility of pharmaceutical supply chains. In the wake of the pandemic, the healthcare sector requires an agile and robust supply chain risk management system to address disruptions, ensure resilience, and smooth operations.

In recent years, supply chain risk management practices have been revolutionised by technology, with new innovations and risk management solutions reducing accessibility concerns through real-time insights and data-driven mitigation strategies. The use of disruptive technologies and Supply Chain Risk Management (SCRM) can help minimise risks by identifying disruptions, preparing contingency plans, and alleviating their overall impact.

Strengthening Healthcare SCRM Strategies to Overcome Accessibility Disparities

Blockchain-enabled healthcare supply chains and IoT sensors facilitate comprehensive, secure, and traceable real-time risk assessments. Predictive analytics and artificial intelligence algorithms can help identify and mitigate disruptions, ensuring patient accessibility.

Zuellig Pharma, a leading healthcare solutions company with a purpose of making healthcare more accessible, harnesses the transformative potential of disruptive technologies to enhance supply chain resilience, agility, and responsiveness to risks, developing a connected pharmaceutical ecosystem through innovative digital platforms.

この蚘事は BioSpectrum Asia の October 2024 版に掲茉されおいたす。

7 日間の Magzter GOLD 無料トラむアルを開始しお、䜕千もの厳遞されたプレミアム ストヌリヌ、9,000 以䞊の雑誌や新聞にアクセスしおください。

この蚘事は BioSpectrum Asia の October 2024 版に掲茉されおいたす。

7 日間の Magzter GOLD 無料トラむアルを開始しお、䜕千もの厳遞されたプレミアム ストヌリヌ、9,000 以䞊の雑誌や新聞にアクセスしおください。

BIOSPECTRUM ASIAのその他の蚘事すべお衚瀺
BioPharma's Transformative & Strategic OUTLOOK 2025
BioSpectrum Asia

BioPharma's Transformative & Strategic OUTLOOK 2025

The Indian biopharma industry witnessed notable transformative developments and announcements, marked by innovation, regulatory advancements, and market expansion this year. From achieving global recognition in biosimilars to advancing biomanufacturing capabilities and precision therapeutics, the sector has solidified its role as a key player in the global pharmaceutical landscape. This progress underscores India's strategic focus on leveraging its robust infrastructure, skilled talent pool, and government support to meet the evolving demands of the healthcare industry.

time-read
10+ 分  |
December 2024
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
BioSpectrum Asia

Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time

US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
BioSpectrum Asia

Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine

Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Spider venom heart drug moves to clinical trials in Australia
BioSpectrum Asia

Spider venom heart drug moves to clinical trials in Australia

A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).

time-read
1 min  |
BioSpectrum Asia Nov 2024
India develops portable ultrasound scanner for sports injury diagnosis
BioSpectrum Asia

India develops portable ultrasound scanner for sports injury diagnosis

A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Victor Ambros and Gary Ruvkun win 2024 Nobel Prize in Physiology or Medicine for discovery of microRNA
BioSpectrum Asia

Victor Ambros and Gary Ruvkun win 2024 Nobel Prize in Physiology or Medicine for discovery of microRNA

The Nobel Assembly at Karolinska Institutet has decided to award the 2024 Nobel Prize in Physiology or Medicine jointly to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation.

time-read
1 min  |
BioSpectrum Asia Nov 2024
University of Hong Kong to establish Global Innovation Centre
BioSpectrum Asia

University of Hong Kong to establish Global Innovation Centre

To consolidate Hong Kong's leading position in basic research, the University of Hong Kong (HKU) is planning to establish the Global Innovation Centre (GIC), an upstream technology research facility, in Pokfulam.

time-read
1 min  |
BioSpectrum Asia Nov 2024
"Australia is a great place to do business as we have a superb research community, great partners and very experienced clinical trial units"
BioSpectrum Asia

"Australia is a great place to do business as we have a superb research community, great partners and very experienced clinical trial units"

Noxopharm Limited, an Australian biotech company, is making strides in the fight against cancer and inflammation with its innovative technology platforms, Chroma and Sofra.

time-read
5 分  |
BioSpectrum Asia Nov 2024
"To achieve our 'Skilled India' vision, we'll train a large number of individuals quickly and to high standards"
BioSpectrum Asia

"To achieve our 'Skilled India' vision, we'll train a large number of individuals quickly and to high standards"

Jayant Singh Chaudhary, Union Minister of State (Independent Charge), Skill Development and Entrepreneurship, Government of India, in an interaction with BioSpecturm in Hyderabad, shares his insights on the various initiatives taken up by the Centre for skill development programmes, boosting self-employment.

time-read
5 分  |
BioSpectrum Asia Nov 2024
Digital Innovations in Diabetes Care
BioSpectrum Asia

Digital Innovations in Diabetes Care

Diabetes affects 537 million people globally and is a major contributor to the non-communicable disease NCD) epidemic. Technological tools such as continuous glucose monitors CGMs) and mobile apps are redefining diabetes management. On this World Diabetes Day November 14, 2024), we explore how digital health is transforming diabetes care and the challenges associated with its integration into healthcare systems.

time-read
5 分  |
BioSpectrum Asia Nov 2024